Intermittent Fasting and Cancer

Research suggests that intermittent fasting may have a protective effect on cancer incidence and progression, as well as improve the recovery experience on cancer patients.

Studies in animals

Prolonged fasting is also known to enhance pro-growth signaling and increase activity in pathways that enhance resistance to toxins. In particular, during treatment of cancer with chemotherapy, starvation preferentially protects host cells, but not cancer cells. Indeed, a link between insulin-like growth factor 1 (IGF-1) levels and chemotherapy protection has been shown.1

It is thought that a great deal of the short and long-term side effects from chemotherapy results from the damage to bone marrow, and the production of immune cells in the blood. Multiple cycles of prolonged fasting have been shown to reduce the immunosuppression and mortality due to chemotherapy, as well as reverse the age-dependent reduction in immunity.2

Studies have shown that intermittent fasting in rats prone to developing cancer, resulted in lower overall incidence rates of neoplasia.3

© 2017 HVMN, Inc. All Rights Reserved.

For informational purposes only. These statements have not been evaluated by the FDA. Products are not intended to diagnose, treat, cure, or prevent any disease.